-
.
02/09/57 . 1
-
02/09/57 . 2
-
02/09/57 . 3
-
.. 2530-2553 ()
4
0
20,000
40,000
60,000
80,000
100,000
120,000
2
5
3
0
2
5
3
1
2
5
3
2
2
5
3
3
2
5
3
4
2
5
3
5
2
5
3
6
2
5
3
7
2
5
3
8
2
5
3
9
2
5
4
0
2
5
4
1
2
5
4
2
2
5
4
3
2
5
4
4
2
5
4
5
2
5
4
6
2
5
4
7
2
5
4
8
2
5
4
9
2
5
5
0
2
5
5
1
2
5
5
2
2
5
5
3
2
5
5
4
Local manuf
Import
0
10,000
20,000
30,000
40,000
50,000
60,000
70,000
80,000
90,000Local_44-53
Import_44-5314.2
7.7
8.6
4.5
4.7
1.320.6
3.5
6.7
8.1
8.8
0.5 7.4
2.40.6
0.3 Alimentary-Metabol
Blood productsCV systemDermatologicals
Genito-urinary-sex horSyst hormonal prep
Syst anti-infectivesHospital solnAntineoplastics
Musculo-sleletalCNS
ParasitologyRespiratory systSensory org
: .
( . 12 .. 2557)02/09/57 .
-
7,540,484
5,918,560
5,849,175 4,827,097 3,228,277
3,064,206
2,886,648
2,429,222
2,350,956 1,958,710
USA
Switzerland
Germany
France
United Kingdom
Italy
India
Japan
China
Belgium
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
1,400,000
1,600,000
2552 2553 2554 2555 2556
IndonesiaPhilippines
SingaporeMalaysia
10 ..2556 ()
ASEAN .. 2552-2556 ()
5( . 12 .. 2557)02/09/57 .
-
1. Drug registration & re-evaluation
post-marketing surveillance
2. Distribution
( . . 2550)02/09/57 . 6
-
()
3. Quality of pharmaceutical products
4. Accessibility 5. Drug use
( . . 2550)02/09/57 . 7
-
1.
2. .2 .1
3. (role model) (peer approval/ social norm)
1
()
(Antimicrobial resistance : AMR,2553)
90,000 / 38,000 / 6,000 / 30,000
.892 URI 50-60% Acute diarrhea 50% 280 URL 65 80% 285 9 .
80%
2535 30 %
2542 . 53.98%
2547 2551 26.3%
2551 2552 17.87% ( 1,584 )
1. steroid abuse ~ 6 ~ 0.38 ~ 1,900 /2. steroid abuse 2.1
steroid abuse 93 1,000
( 100, ./. 61, 96, 101, 131 1,000 ) 2.2 steroid abuse 6.4 100
2.3 Cushings syndrome (48/1,000),
metabolic disorders (43/1,000), adrenal crisis (4/1,000),
adrenal insufficiency (9/1,000), GI 4.8 3 ()
3
2
802/09/57 . 8
-
()
6. Traditional & herbal medicines
6.1 R&D, local production and quality assurance
6.2 Selection and distribution OTOP
6.3 Drug use
( . . 2550)
02/09/57 . 9
-
: .. 2557 1
10
7,700
1,000
14
7 .
()
02/09/57 . 10
-
..
02/09/57 . 11
-
.. 2558
(website 2556( . 12 .. 2557)
/
1202/09/57 .
-
Harmonizationconvergencecollaboration: NDRAs NDRAs
(HTA)
: personalized medicines, pharmaceutical products with delivery
devices/vehicles,
13 ( . 12 .. 2557)02/09/57 .
-
..
2551
.. 2510
.. 2554
.. 2554 2559
Pre-marketing control
Post-marketing control - -
ACCESS SAFETY & EFFICACY AFFORDABILITY
02/09/57 . 14
-
15
( .. 2554
..2555 - 2559)
(..2524 / ..2536)
(..2551 - )
.. 2551
... ( ... .. ....)
02/09/57 .
-
()
. . . . . . . .
02/09/57 . 16
-
www.fda.moph.go.thwww.oryor.com
http://www.facebook.com/fdathai
02/09/57 . 17
